In March, Levofloxacin Hemihydrate in the US market firmed as import-parity offers strengthened and restocking progressed. Indian exporters raised export quotations while GMP operating rates were maintained, reducing exportable surplus. Hospital tenders prompted distributors to rebuild safety stock after winter drawdowns. Freight surcharges on the Asia–U.S. West Coast and batch validations constrained spot availability, with Los Angeles bonded inventory at the lower end of ranges. The result was an upward bias driven by healthcare restocking and tighter Indian export flows. Demand remained strongest in the healthcare channel, with hospitals and group-purchasing organizations securing tenders for anti-infectives and finished-dose products; retail pharmacy contributed steady pull-through for Tier-6 antibiotics. Conversely, Indian API producers pulled additional volumes for internal use, further tightening exportable supply. Logistics costs supported the delivered premium; Indian export dependence remained high, with domestic sourcing limited. Near-term momentum is expected to endure, with forecasts for gains before a modest pause later in the year, subject to feedstock and policy dynamics.
